AmerisourceBergen to pay $625 million to settle civil fraud case

Oct 01, 2018

U.S. drug wholesaler AmerisourceBergen will pay $625 million to resolve civil fraud charges over the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors.

The settlement was announced by the U.S. Department of Justice boosts AmerisourceBergen’s total payout to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration.

Last year, AmerisourceBergen pled guilty to illegally distributing misbranded drugs and agreed to pay $260 million to resolve criminal liability for its distribution of these drugs from a facility that was not registered with the Food and Drug Administration (FDA). The settlement resolves the company's civil liability to the United States under the False Claims Act for causing false claims for the drugs it repackaged to be submitted to federal health care programs.  

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!